Company intelligence / Profile preview

BGN Technologies

Beer Sheva, Israel

Ownership: Private
Development stage: Other

Overview

BGN Technologies acts as Ben-Gurion University's tech transfer company, linking academia with industry, commercializing hundreds of patents including those for new cancer therapeutics, anti-biofilm agents, and enabling technologies for cell anomaly detection; most programs are at the invention or startup stage, not direct clinical results[1][2][3][4][7].

Therapeutic areas: OncologyInfectious DiseasesOther
Modalities: Small moleculeAntisense oligonucleotideProteinRecombinant proteinNanoparticle
Industry: Drug Discovery Services

Partnerships

Sorrento Therapeutics[6]William Marsh Rice University[7]Regents of University of Minnesota[7]Nanyang University[7]GM Global Technology Operations LLC[7]University of Connecticut[7]

Beyond the preview

Go deeper on BGN Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGN Technologies.

Explore the full profile